Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2023 1
2024 36
2025 10
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

44 results

Results by year

Filters applied: . Clear all
Page 1
The power of three: Retatrutide's role in modern obesity and diabetes therapy.
Abdul-Rahman T, Roy P, Ahmed FK, Mueller-Gomez JL, Sarkar S, Garg N, Femi-Lawal VO, Wireko AA, Thaalibi HI, Hashmi MU, Dzebu AS, Banimusa SB, Sood A. Abdul-Rahman T, et al. Eur J Pharmacol. 2024 Dec 15;985:177095. doi: 10.1016/j.ejphar.2024.177095. Epub 2024 Nov 6. Eur J Pharmacol. 2024. PMID: 39515565 Review.
As a transformative therapeutic modality, retatrutide represents a beacon of hope, signifying transformative changes in the management landscape of obesity and type 2 diabetes mellitus (T2DM), and warranting continued exploration and refinement in clinical practice. …
As a transformative therapeutic modality, retatrutide represents a beacon of hope, signifying transformative changes in the managemen …
Emerging pharmacotherapies for obesity: A systematic review.
Kokkorakis M, Chakhtoura M, Rhayem C, Al Rifai J, Ghezzawi M, Valenzuela-Vallejo L, Mantzoros CS. Kokkorakis M, et al. Pharmacol Rev. 2025 Jan;77(1):100002. doi: 10.1124/pharmrev.123.001045. Epub 2024 Nov 22. Pharmacol Rev. 2025. PMID: 39952695 Free article.
However, categories of emerging pharmacotherapies generate hope to reduce obesity rates. This systematic review of phase 2 and phase 3 trials in adults with overweight/obesity investigates the effect of novel weight loss pharmacotherapies, compared to placebo/contro …
However, categories of emerging pharmacotherapies generate hope to reduce obesity rates. This systematic review of phase 2 and phase …
What is the pipeline for future medications for obesity?
Melson E, Ashraf U, Papamargaritis D, Davies MJ. Melson E, et al. Int J Obes (Lond). 2025 Mar;49(3):433-451. doi: 10.1038/s41366-024-01473-y. Epub 2024 Feb 1. Int J Obes (Lond). 2025. PMID: 38302593 Free PMC article. Review.
Obesity is a chronic disease associated with increased risk of obesity-related complications and mortality. ...Tirzepatide, a dual GLP-1/GIP receptor agonist has been approved for glycaemic control in type 2 diabetes as well as for obesity management leading …
Obesity is a chronic disease associated with increased risk of obesity-related complications and mortality. ...Tirzepatide, a …
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity.
Drucker DJ. Drucker DJ. Diabetes Care. 2024 Nov 1;47(11):1873-1888. doi: 10.2337/dci24-0003. Diabetes Care. 2024. PMID: 38843460 Review.
The development of glucagon-like peptide 1 receptor agonists (GLP-1RA) for type 2 diabetes and obesity was followed by data establishing the cardiorenal benefits of GLP-1RA in select patient populations. ...Simultaneously, investigational molecules such as maritide block t …
The development of glucagon-like peptide 1 receptor agonists (GLP-1RA) for type 2 diabetes and obesity was followed by data establish …
Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials.
Moiz A, Filion KB, Toutounchi H, Tsoukas MA, Yu OHY, Peters TM, Eisenberg MJ. Moiz A, et al. Ann Intern Med. 2025 Feb;178(2):199-217. doi: 10.7326/ANNALS-24-01590. Epub 2025 Jan 7. Ann Intern Med. 2025. PMID: 39761578
BACKGROUND: Recent randomized controlled trials (RCTs) have investigated glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual or triple co-agonists for weight loss among adults with overweight or obesity and without diabetes. PURPOSE: To assess the efficacy and s …
BACKGROUND: Recent randomized controlled trials (RCTs) have investigated glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual or t …
Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition?
Locatelli JC, Costa JG, Haynes A, Naylor LH, Fegan PG, Yeap BB, Green DJ. Locatelli JC, et al. Diabetes Care. 2024 Oct 1;47(10):1718-1730. doi: 10.2337/dci23-0100. Diabetes Care. 2024. PMID: 38687506 Review.
Liraglutide and semaglutide (GLP-1RA), tirzepatide (GLP-1 and GIP receptor dual agonist), and retatrutide (GLP-1, GIP, and glucagon receptor triple agonist) are peptides with incretin agonist activity that induce 15-24% weight loss in adults with overweight and obesity …
Liraglutide and semaglutide (GLP-1RA), tirzepatide (GLP-1 and GIP receptor dual agonist), and retatrutide (GLP-1, GIP, and glucagon r …
Gut hormones and appetite regulation.
Hong SH, Choi KM. Hong SH, et al. Curr Opin Endocrinol Diabetes Obes. 2024 Jun 1;31(3):115-121. doi: 10.1097/MED.0000000000000859. Epub 2024 Mar 21. Curr Opin Endocrinol Diabetes Obes. 2024. PMID: 38511400 Review.
Environmental factors including meal schedule, food contents and quality, type of exercise, and sleep deprivation also play a role in the influence of gut hormone on appetite, weight change, and obesity. Recently published studies have shown that retatrutide, a trip …
Environmental factors including meal schedule, food contents and quality, type of exercise, and sleep deprivation also play a role in the in …
Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials.
Abdrabou Abouelmagd A, Abdelrehim AM, Bashir MN, Abdelsalam F, Marey A, Tanas Y, Abuklish DM, Belal MM. Abdrabou Abouelmagd A, et al. Proc (Bayl Univ Med Cent). 2025 Feb 5;38(3):291-303. doi: 10.1080/08998280.2025.2456441. eCollection 2025. Proc (Bayl Univ Med Cent). 2025. PMID: 40291085 Free PMC article. Review.
We sought to assess the efficacy and safety of retatrutide in obese patients with or without diabetes. METHODS: PubMed, Scopus, Web of Science, and Cochrane databases were searched from inception until May 2024. Eligible studies comprised randomized controlle …
We sought to assess the efficacy and safety of retatrutide in obese patients with or without diabetes. METHODS: PubMed, Scopus …
A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity.
Kaur M, Misra S. Kaur M, et al. Eur J Clin Pharmacol. 2024 May;80(5):669-676. doi: 10.1007/s00228-024-03646-0. Epub 2024 Feb 17. Eur J Clin Pharmacol. 2024. PMID: 38367045 Review.
The Phase III trial of this pipeline drug for treating type 2 diabetes mellitus, non-alcoholic fatty liver disease, and obesity started on August 28, 2023. The results of a Phase II clinical trial have demonstrated significant weight reduction in overweight and obese …
The Phase III trial of this pipeline drug for treating type 2 diabetes mellitus, non-alcoholic fatty liver disease, and obesity start …
The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation.
Stefanakis K, Kokkorakis M, Mantzoros CS. Stefanakis K, et al. Metabolism. 2024 Dec;161:156057. doi: 10.1016/j.metabol.2024.156057. Epub 2024 Oct 30. Metabolism. 2024. PMID: 39481534 Review.
Similar to bariatric surgery, incretin receptor agonists have revolutionized the treatment of obesity, achieving up to 15-25 % weight loss in many patients, i.e., at a rate approaching that achieved with bariatric surgery. ...For the time being, considerations like advance …
Similar to bariatric surgery, incretin receptor agonists have revolutionized the treatment of obesity, achieving up to 15-25 % weight …
44 results